Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Related Articles
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Solid Pseudopapillary Tumor of the Pancreas: Is Enucleation Safe?
Annals of Surgical Oncology – While solid pseudopapillary tumor (SPT) of the pancreas are oncologically low-risk tumors, their resection with pancreaticoduodenectomy (PD) or partial pancreatectomy…
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…
Unlocking the Potential of Patient Navigation: New CPT Codes Pave the Way for Enhanced Oncology Care
Explore the 2024 CPT codes for oncology patient navigation and how pharma can support improved patient outcomes.
Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
New-Onset Diabetes and Pancreatic Cancer: An Important Link
Pancreatic cancer is a tough disease to catch early because it doesn’t always cause clear symptoms right away. Still, noticing changes in your body can…
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they…
The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
FDA Grants Priority Review to Avutometinib/Defactinib Combo in KRAS+ Ovarian Cancer
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.